Ohio State Navbar

Sign In

RSS Feed Regenerative Medicine News


ReNeuron Receives DSMB Clearance to Progress to Higher Dose in Stem Cell Clinical Trial in Disabled Stroke Patients: First Patient Treated in this Higher Dose Cohort 

 

 

ReNeuron Receives DSMB Clearance to Progress to Higher Dose in Stem Cell Clinical Trial in Disabled Stroke Patients: First Patient Treated in this Higher Dose Cohort

August 14, 2012 - (ReNeuron) - "ReNeuron provides an update on progress with the PISCES clinical trial of its ReN001 stem cell therapy for disabled stroke patients. In this open label, dose-ranging Phase I safety study, taking place in Scotland, ReNeuron’s ReN001 stem cell therapy is being administered in ascending doses to a total of 12 stroke patients who have been left disabled by an ischaemic stroke, the most common form of the condition."  Read Full Article

 

Posted on 23-Aug-12 by Toto, Brent
Tags: Science and Industry News
 
Trackback Url  |  Link to this post | Bookmark this post with: